CLINICAL_TRIALS trial_result · 2023-01-20

Clinical Trial Update: A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients [Phase 3]

Phase 3 trial evaluating HS-10296 as first-line treatment for non-small cell lung cancer. Status and results are not provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN | Results posted: 2023-01-20